慢性髓性白血病患者的COVID-19
研究通过问卷调查湖北省530例慢性髓性白血病(CML)患者,5例确诊或疑似COVID-19,患病率0.9%(95%CI 0.1–1.8%),为正常人群0.1%的九倍,但低于住院其他血液肿瘤患者或正常医护人员10%和7%。与COVID-19风险增加相关的因素包括接触SARS-CoV-2感染者、无完全血液学反应、合并症及晚期CML。
要点
- CML患者COVID-19患病率为0.9%(95%CI 0.1–1.8%),为正常人群0.1%的九倍。
- 接触感染者(P=0.037)、无完全血液学反应(P=0.003)、合并症(P=0.024)与COVID-19风险增加相关。
- 晚期CML患者即使达到完全细胞遗传学或主要分子学反应,COVID-19风险仍增加(P=0.004)。
核心结论
- CML患者中COVID-19患病率为0.9%(95%CI 0.1–1.8%),高于正常人群但低于住院其他血液肿瘤患者或正常医护人员。
- 具有接触感染者、无完全血液学反应、合并症或晚期CML等风险因素的患者可能受益于加强SARS-CoV-2感染监测和可能的保护性隔离。
研究设计与样本
- 通过问卷调查研究湖北省530例慢性髓性白血病(CML)患者。
主要发现
- 5例发生确诊(N=4)或疑似(N=1)COVID-19。
- CML患者COVID-19患病率为0.9%(95%CI 0.1–1.8%),正常人群为0.1%(95%CI 0–0.12%),住院其他血液肿瘤患者或正常医护人员为10%(95%CI 6–17%)和7%(95%CI 4–12%)。
- 与COVID-19风险增加相关的因素包括接触SARS-CoV-2感染者(P=0.037)、无完全血液学反应(P=0.003)和合并症(P=0.024)。
- 晚期CML患者即使达到完全细胞遗传学反应或主要分子学反应,COVID-19风险仍增加(P=0.004)。
- 接受第三代TKI的21例中1例发生COVID-19,接受伊马替尼的346例中3例,接受第二代TKI的162例中0例(P=0.096)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.
引用
- Li W, Wang D, Guo J, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020. PMID: 32424293. doi:10.1038/s41375-020-0853-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。